AIM ImmunoTech Inc. financial data

Symbol
AIM on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
2117 Sw Highway 484, Ocala, FL
State of incorporation
DE
Fiscal year end
December 31
Former names
HEMISPHERX BIOPHARMA INC (to 8/26/2019)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 184 % -88.2%
Return On Equity -256 % -385%
Return On Assets -142 % -189%
Operating Margin -15.7K % -21.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 57.1M shares +17.4%
Common Stock, Shares, Outstanding 57.1M shares +18%
Entity Public Float 31.8M USD -12.2%
Common Stock, Value, Issued 57K USD +18.8%
Weighted Average Number of Shares Outstanding, Basic 52.8M shares +9.14%
Weighted Average Number of Shares Outstanding, Diluted 52.8M shares +9.14%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 201K USD +18.9%
Revenue from Contract with Customer, Excluding Assessed Tax 201K USD +18.9%
Research and Development Expense 9.03M USD +6.44%
General and Administrative Expense 22.7M USD +66.1%
Costs and Expenses 31.8M USD +44.5%
Operating Income (Loss) -31.6M USD -44.7%
Net Income (Loss) Attributable to Parent -28M USD -45%
Earnings Per Share, Basic -0.57 USD/shares -42.5%
Earnings Per Share, Diluted -0.57 USD/shares +70%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.55M USD -83.1%
Marketable Securities, Current 6.51M USD -11.6%
Accounts Receivable, after Allowance for Credit Loss, Current 1.18M USD -29.4%
Assets, Current 10.4M USD -64.1%
Property, Plant and Equipment, Net 109K USD -24.8%
Operating Lease, Right-of-Use Asset 700K USD -10.4%
Other Assets, Noncurrent 2.05M USD +15.1%
Assets 15.7M USD -53.3%
Accounts Payable, Current 5.46M USD +154%
Employee-related Liabilities, Current 1K USD -97.2%
Accrued Liabilities, Current 799K USD +51.3%
Liabilities, Current 8.84M USD +206%
Operating Lease, Liability, Noncurrent 488K USD -18.3%
Liabilities 9.61M USD
Retained Earnings (Accumulated Deficit) -417M USD -7.21%
Stockholders' Equity Attributable to Parent 6.1M USD -79.8%
Liabilities and Equity 15.7M USD -53.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.82M USD -30.8%
Net Cash Provided by (Used in) Financing Activities 2.83M USD +2729%
Net Cash Provided by (Used in) Investing Activities -158K USD -103%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 57.1M shares +18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.14M USD +41.4%
Deferred Tax Assets, Valuation Allowance 36.8M USD +19.4%
Deferred Tax Assets, Gross 38.4M USD +20.2%
Operating Lease, Liability 722K USD -10.1%
Depreciation 9K USD -18.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -28M USD -45%
Property, Plant and Equipment, Gross 1.45M USD
Operating Lease, Liability, Current 234K USD +13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 244K USD +10.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 273K USD +3.41%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 107K USD -33.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 159K USD -20.5%
Deferred Tax Assets, Operating Loss Carryforwards 25.1M USD +27.7%
Preferred Stock, Shares Authorized 5M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 133K USD -33.5%
Additional Paid in Capital 423M USD +1.12%
Amortization of Intangible Assets 49K USD +36.1%
Interest Expense 179K USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares